Brought to you by 
Abbott to sell Vysis DNA cancer tests
04 Mar 2002
Executive Summary
Abbott Laboratories will exclusively sell two of Vysis's (a unit of BP Amoco; develops genetics tests) DNA-based cancer tests in N. America and Europe, and has an exclusive option to also distribute them in S. America and Asian/Pacific regions outside of Japan.
Deal Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott to sell Vysis DNA cancer tests
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice